Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 99. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Ordinary people in extraordinary times1944
A step forward in the journey towards hookworm vaccines1430
Adaora “Ada” Alise Adimora980
Reflecting on lessons from the 2014–16 Ebola virus outbreak886
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7713
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial621
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis609
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations532
Updated criteria for paediatric sepsis and septic shock480
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial398
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic340
Highlights from the sixth ESCMID Conference on Vaccines317
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges316
DNDi receives Dutch funding boost297
HIV vaccine trial failure283
Research in brief271
Transitioning to endemicity with COVID-19 research268
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum267
Attention to skin-related neglected tropical diseases260
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines254
Research in brief252
COVID-19 vaccination protects children and adolescents239
A patient with secondary syphilis following incomplete treatment of primary infection234
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations234
Environment and infectious diseases227
Surge of cutaneous leishmaniasis in Pakistan217
Infectious disease surveillance update210
The lasting lessons of mpox: infection, vaccination, and immune memory208
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review205
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C202
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study200
Measles immunity gaps and outbreak risk in a shifting landscape199
Correction to Lancet Infect Dis 2025; 25: e280–93195
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting192
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation190
The superiority of bivalent over monovalent booster vaccines186
Best practice guidelines for viral hepatitis service delivery in prisons183
Promoting diversity and equity in publishing180
Shaping opportunities for future clinical trials in tuberculosis177
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom177
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 177
Kyasanur Forest disease: an emerging arboviral threat175
Threat of HIV and tuberculosis drug resistance after US funding cuts173
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1171
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial169
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden167
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study164
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study162
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer162
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco160
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect160
Listeria monocytogenes: a rare, deadly cause of peritonitis156
The next chapter for Africa's genomic initiatives155
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria151
The importance of understanding the infectious microenvironment149
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial148
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin147
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study140
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis140
Mpox in people with past infection or a complete vaccination course: a global case series138
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2138
Research in brief136
Global cholera resurgence—a preventable tragedy134
New flavours of tuberculosis treatment for children132
Research in brief132
Correction to Lancet Infect Dis 2025; 25: e47–58131
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation130
Patient-centred approaches for drug-resistant tuberculosis130
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study129
Curing chronic hepatitis B virus infection129
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine127
WHO's first global infection prevention and control report127
Malaria vaccine development in Mali: a step towards transmission-blocking strategies126
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant125
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents125
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study123
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia123
Post-viral sequelae of COVID-19 and influenza122
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis121
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5120
Addressing the shortage of cholera vaccines118
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms116
The implications of mpox breakthrough infections on future vaccination strategies116
A new monoclonal in the arMAMentarium against malaria114
Theresa Ochoa—staying on top of infectious diseases in Peru112
Infectious disease surveillance update111
Correction to Lancet Infect Dis 2025; 25: e622110
Research in brief110
Assessment of experimental malaria vaccine induced protection in pre-exposed populations109
RSV prevention: public health lessons from the southern hemisphere109
Worrying lack of funding for tuberculosis107
Full-dose NSAIDs at the first sign of respiratory infection?106
Severe influenza: is there a role for antiviral combinations?105
Tuberculosis recovery in Georgia: implementing more by 24104
Correction to Lancet Infect Dis 2023; 23: e469104
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa101
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86100
Election of Regional Director for the Western Pacific100
Emil Gotschlich99
0.051330089569092